Cell Medica Raises £60M for Phase II T-Cell Product and Cell Immunotherapy Pipeline – Genetic Engineering & Biotechnology News
|
Cell Medica Raises £60M for Phase II T–Cell Product and Cell Immunotherapy Pipeline
Genetic Engineering & Biotechnology News Cell Medica is exploiting its activated cytotoxic T cell technology, and chimeric antigen receptor (CAR), and engineered T cell receptors (TCR) platforms to develop a pipeline of cell-based immunotherapies for applications in cancer therapy and immune … Cell Medica: £60 Million Series C Financing to Advance Multiple Cancer Programmes |
